Literature DB >> 23775889

Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm.

Deborah Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23775889     DOI： 10.1136/bmj.f3900

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!

Authors:  Michael A Nauck; Juris J Meier
Journal:  J Diabetes Sci Technol       Date:  2014-05-12

Review 2.  Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.

Authors:  Ling Li; Jiantong Shen; Malgorzata M Bala; Jason W Busse; Shanil Ebrahim; Per Olav Vandvik; Lorena P Rios; German Malaga; Evelyn Wong; Zahra Sohani; Gordon H Guyatt; Xin Sun
Journal:  BMJ       Date:  2014-04-15

3.  Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.

Authors:  Edwin A M Gale
Journal:  Diabetes Care       Date:  2013-12       Impact factor: 19.112
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.